

Special Issue

The Variant-Based Dynamics of SARS-CoV-2 and Other Viral Diseases

Message from the Guest Editors

Understanding the role of variants in an epidemic/pandemic is essential to understand the dynamics of these diseases which, in turn, is crucial for developing efficient prevention approaches. A priority is to understand what a variant is from both an evolutionary and functional standpoint. It is essential to characterize this process of generation and succession of variants from different angles, i.e., genetics, evolution, selection adaptation, function, transmissibility, virulence, epidemiology, host interaction, host range, multi-host dynamics, modeling, interaction with the immune system, etc. Virus variants represent a significant threat to vaccines. There is a risk that new variants may overcome the protection offered by a vaccine. Investigating virus variant selection and evolution in regard to vaccines is thus another key issue to be addressed. This Special Issue aims to gather works addressing all aspects of viral variant analysis. This Special Issue will welcome all kinds of articles, e.g., reviews, short reports, hypotheses, research articles, opinions, and comments, on all families of viruses.

Guest Editors

Prof. Dr. Roger Frutos

CIRAD, University of Montpellier, Montpellier, France

Dr. Jordi Serra-Cobo

Department of Animal Biology, Universitat de Barcelona, Barcelona, Spain

Deadline for manuscript submissions

closed (21 June 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/102091

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

